Articles

Although ibrutinib is generally cost-effective in first-line use compared with chemotherapy and chemoimmunotherapy, a subset of ibrutinib-treated patients with cardiovascular events had a mitigating impact on the total cost of care. Read More ›

In a phase 3 study, the combination of ibrutinib and rituximab provided superior progression-free survival and overall survival relative to the combination of fludarabine, cyclophosphamide, and rituximab for younger patients with previously untreated chronic lymphocytic leukemia (CLL) Read More ›

Researchers evaluating the Bruton’s tyrosine kinase inhibitor acalabrutinib monotherapy in relapsed/refractory and high-risk, treatment-naïve chronic lymphocytic leukemia (CLL) patients reported high response rates and an acceptable safety profile. Read More ›

Using a national claims database, researchers found that previously untreated patients receiving chemoimmunotherapy had a higher total cost of care compared with patients receiving single-agent ibrutinib. Read More ›

This phase 3 follow-up analysis evaluates the efficacy and safety of ibrutinib, alone and in combination with rituximab, in patients with Waldenström’s macroglobulinemia. Read More ›

In an ex vivo analysis, the combination of venetoclax and ibrutinib showed encouraging biologic activity in several leukemia subtypes, including acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Read More ›

In a phase 2 trial, the combination of ibrutinib and venetoclax was effective in patients with previously untreated, high-risk chronic lymphocytic leukemia (CLL), with no unforeseen safety signals. Read More ›

Researchers evaluated venetoclax plus rituximab versus bendamustine plus rituximab in inducing deep, durable responses in patients with chronic lymphocytic leukemia, as measured by the rate of minimal residual disease. Read More ›

The combination of ibrutinib with obinutuzumab represents an effective chemotherapy-free treatment option for first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities. Read More ›

The Bruton’s tyrosine kinase inhibitor acalabrutinib shows promise as a tolerable, effective monotherapy option for patients with previously untreated chronic lymphocytic leukemia. Read More ›